Cancer Crosslinks was established in 2009, when Oslo Cancer Cluster, in collaboration with Bristol-Myers Squibb organized the first meeting of this kind.
Since then, several Cancer Crosslinks meetings have been arranged in Norway, Sweden and Finland. In 2018, the Norwegian Cancer Crosslinks presented its 10th edition, focusing on Precision Treatment: Exploiting Recent Advances – Fast and Furious?
The goal of the Cancer Crosslinks meetings is to promote interactions between researchers and clinicians, as well as to encourage translational and clinical research, and new collaborations to advance the development of innovative cancer treatments. Cancer Crosslinks Norway has become one of the leading national meeting places gathering oncologists, hematologists, translational researchers, healthcare providers, regulatory experts and industry representatives.
The hallmark of Cancer Crosslinks is the full-day educational program featuring distinguished international and national experts presenting recent advances in oncology. This main program is complemented by tailored activities to stimulate additional interactions and discussions between the Cancer Crosslinks speakers and representatives from the Norwegian Oncology Community.
Missed Cancer Crosslinks 2018 in Oslo?
On January 18,2018, Oslo Cancer Cluster presented the 10th Cancer Crosslinks in Oslo.
This fully-attended conference brought together distinguished international and Norwegian speakers, leading researchers and experts to discuss recent developments in translational research and clinical implementation.
These critical thinkers explored Precision Treatment: Exploiting Recent Advances fast and furiously throughout the day, as they shared their broad and complementary expertise in immuno-oncology, microbiome research, precision medicine and big data.
This engaging forum provided for stimulating interdisciplinary exchanges, novel collaborations, and opportunities to cross-link.
You may watch most of the presentations HERE.
A very special thank you to our speakers:
Cancer Immunotherapy – The Journey So Far and Where We Are Heading
Jeffrey S. Weber, Professor, Deputy Director and Co-Director of Melanoma Program; Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, USA
The Microbiome Cancer and Cachexia Professor
Laure Bindels, Louvain Drug Research Institute, Université catholique de Louvain, Belgium
From Feasibility to Utility in Precision Cancer Medicine – Experiences from the First Norwegian Study of NGS-Based Therapy Decisions in Advanced Cancer
Hege G. Russnes, Senior Consultant and Researcher, Oslo University Hospital, The Norwegian Radium Hospital
Anne Hansen Ree, Professor, Akershus University Hospital, University of Oslo
Precision Medicine for Gynecologic Cancers – Opportunities and Obstacles
Douglas A. Levine, Professor, Director Gynecologic Oncology, Laura and Isaac Perlmutter Cancer Center & Head, Gynecology Research Laboratory, NYU Langone Medical Center, New York, USA
Roadmap for European Hematology Research and Hodgkin Lymphoma: (Immuno)therapy, Late Effects and the Way Forward
Andreas Engert, Professor for Internal Medicine, Hematology and Oncology, University Hospital of Cologne, Germany
The Next Generation of Engineered T-cells för immunotherapy of Hematological and Solid Tumors
Marcela V. Maus, Assistant Professor, Harvard Medical School & Director of Cellular Immunotherapy Cancer Center, Massachusetts General Hospital, Boston, USA
Making Sense of Big Data for Oncology Patients – Vision and Reality
Marc Vaudel, Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital and KG Jebsen Center for Diabetes Research, Department of Clinical Science, University of Bergen
Elisabeth Wik, Centre for Cancer Biomarkers, University of Bergen and Department of Pathology, Haukeland University Hospital
Thank you, Jarle Breivik, Professor, University of Oslo, for your analysis about “The Good Luck Theory of Cancer” during the evening program.
We would like to thank all our partners from industry and academia, speakers and chairpersons, scientific committee members, and experts for their contributions towards shaping and
delivering the Cancer Crosslinks series in collaboration with Oslo Cancer Cluster.
A special acknowledgement to our sponsors:
This special acknowledgement goes to Bristol-Myers Squibb, who has been a partner since the 1st Cancer Crosslinks, and to Takeda Oncology for their partnership during this year’s event.
The 10th Cancer Crosslinks, 2018 was held at Oslo Cancer Cluster Innovation Park in Oslo on Thursday, January 18, 2018 at Kaare Norum Auditorium.